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Correction {#jah32602-sec-0001}
==========

In the article by AbouEzzeddine et al "Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction," which published on February 18, 2017, and appeared in the February 2017 issue of the journal (*J Am Heart Assoc*. 2017;6:e004382. DOI: [10.1161/JAHA.116.004382](10.1161/JAHA.116.004382).), the authors mistakenly referred to the ST2 as Suppression of Tumorigenicity 2, an entirely unrelated gene. The gene that is commonly reported as being a biomarker that is upregulated in heart failure and other systemic inflammatory diseases (and that the authors intended to refer to in this manuscript) is the gene IL1RL1 (interleukin 1 receptor like 1). Ambiguously, this was originally also termed ST2; hence the error that has been commonly made in the literature. The article has been corrected and all reference to Suppression of Tumorigenicity 2 has been corrected to Soluble ST2.

The authors regret the error.

The online version of the article has been updated and is available at <http://jaha.ahajournals.org/content/6/2/e004382>
